10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
MERCK & CO., INC. | |||
Ticker: MRK Fiscal Year: 2012 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2012 10-K (Filed: Feb 28, 2013) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | |
| Cash Flows from Operating Activities | |||
| Net income | $ 6,299 | 6,392 | 982 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation and amortization | 6,978 | 7,427 | 7,381 |
| Intangible asset impairment charges | 200 | 705 | 2,441 |
| Gain on disposition of interest in equity method investment | (136) | ||
| Gain on AstraZeneca LP asset option exercise | (443) | ||
| Equity income from affiliates | (642) | (610) | (587) |
| Dividends and distributions from equity affiliates | 291 | 216 | 324 |
| Deferred income taxes | 669 | (1,537) | (1,092) |
| Share-based compensation | 335 | 369 | 509 |
| Other | 28 | 323 | 377 |
| Net changes in assets and liabilities: | |||
| Accounts receivable | 349 | (1,168) | (1,089) |
| Inventories | (482) | (678) | 1,990 |
| Trade accounts payable | (302) | 182 | 124 |
| Accrued and other current liabilities | (717) | 1,444 | 35 |
| Income taxes payable | (34) | (277) | 128 |
| Noncurrent liabilities | (1,747) | (7) | (98) |
| Other | (1,203) | (262) | (160) |
| Net Cash Provided by Operating Activities | 10,022 | 12,383 | 10,822 |
| Cash Flows from Investing Activities | |||
| Capital expenditures | (1,954) | (1,723) | (1,678) |
| Purchases of securities and other investments | (12,841) | (7,325) | (7,197) |
| Proceeds from sales of securities and other investments | 7,783 | 6,149 | 4,561 |
| Proceeds from sale of interest in equity method investment | 175 | ||
| Acquisitions of businesses, net of cash acquired | (373) | (256) | |
| Dispositions of businesses, net of cash divested | 323 | ||
| Proceeds from AstraZeneca LP asset option exercise | 647 | ||
| Decrease in restricted assets | 34 | 276 | |
| Other | 173 | (116) | 150 |
| Net Cash Used in Investing Activities | (6,805) | (2,890) | (3,497) |
| Cash Flows from Financing Activities | |||
| Net change in short-term borrowings | 624 | 1,076 | 90 |
| Payments on debt | (22) | (1,547) | (1,341) |
| Proceeds from issuance of debt | 2,562 | 1,999 | |
| Purchases of treasury stock | (2,591) | (1,921) | (1,593) |
| Dividends paid to stockholders | (5,116) | (4,691) | (4,734) |
| Other dividends paid | (120) | (120) | (119) |
| Proceeds from exercise of stock options | 1,310 | 321 | 363 |
| Other | 86 | (22) | (106) |
| Net Cash Used in Financing Activities | (3,267) | (6,904) | (5,441) |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | (30) | 42 | (295) |
| Net (Decrease) Increase in Cash and Cash Equivalents | (80) | 2,631 | 1,589 |
| Cash and Cash Equivalents at Beginning of Year | 13,531 | 10,900 | |
| Cash and Cash Equivalents at End of Year | 13,451 | 13,531 | 10,900 |
| External Links | |
| MERCK & CO., INC. (MRK) Fiscal Year 2012 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |